Nasdaq · Healthcare
Biofrontera Inc. (BFRI)
As-reported financials and recent SEC filings for Biofrontera Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$41.7M
Net income
$-10.5M
Net margin
-25.3%
Diluted EPS
$-1.04
ROE
-100.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-11.3M | $-17.2M | $-22.7M | $-18.6M | $-25.2M |
| Net income | $-10.5M | $-17.8M | $-20.1M | $-640,000 | $-37.7M |
| Diluted EPS | $-1.04 | $-3.22 | $-3.25 | $-0.15 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-17
View on EDGAR →10-Q2026-05-14
View on EDGAR →8-K2026-05-14
View on EDGAR →DEF 14A2026-04-30
View on EDGAR →10-K2026-03-19
View on EDGAR →8-K2026-03-19
View on EDGAR →8-K2026-03-09
View on EDGAR →42026-03-06
View on EDGAR →Largest Healthcare peers
Go deeper on BFRI
Search Biofrontera Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.